FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to compounds of formula I and their pharmaceutically acceptable compositions.
EFFECT: technical result is obtaining novel compounds suitable as Bruton tyrosine kinase inhibitors, which can be used to produce medicinal agents for preventive or therapeutic treatment of mediated disorder.
11 cl, 1 tbl, 81 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USE THEREOF | 2014 |
|
RU2703301C2 |
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
| PYRIMIDINE DERIVATIVES AS BTK INHIBITORS AND USE THEREOF | 2016 |
|
RU2743040C2 |
| SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 2018 |
|
RU2817698C2 |
| 6-[4-(1H-IMIDAZOL-2-YL)PIPERIDIN-1-YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | 2014 |
|
RU2674261C2 |
| COMPOUNDS OF TETRAHYDROPYRASOLOPIRIMIDINE | 2013 |
|
RU2677291C2 |
| PYRROLOPYRIMIDINE COMPOUNDS FOR MALIGNANT TUMOUR TREATMENT | 2012 |
|
RU2631655C2 |
| METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS, USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK-INHIBITING ACTIVITY | 2016 |
|
RU2779287C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619465C2 |
| CERTAIN CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS | 2014 |
|
RU2718876C2 |
